|
Mar 24
|
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
|
|
Mar 19
|
Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale
|
|
Mar 19
|
Pfizer Sells $3.5 Billion of Shares in Haleon
|
|
Feb 7
|
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
|
|
Feb 6
|
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
|
|
Feb 6
|
UPDATE 1-US bill poses risk to Wuxi AppTec and its Western drugmaker partners
|
|
Feb 5
|
US bill poses risk to Wuxi AppTec and its Western drugmaker partners
|
|
Feb 3
|
GSK Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 2
|
23andMe is low on cash and its stock is worth pennies. The CEO wants another chance
|
|
Feb 1
|
GSK plc (NYSE:GSK) Q4 2023 Earnings Call Transcript
|
|
Feb 1
|
Drugmaker Abbott India's Q3 profit rises on strong demand
|
|
Jan 31
|
Tech, Media & Telecom Roundup: Market Talk
|
|
Jan 9
|
Stocks to Watch Tuesday: Boeing, Match, HPE, JetBlue
|
|
Jan 9
|
Health Care Roundup: Market Talk
|
|
Jan 9
|
FTSE 100 LIVE: Hays shares slide after 'difficult December', GSK in $1bn respiratory drug deal
|
|
Jan 9
|
GSK to buy asthma treatment firm Aiolos Bio in £1.1bn deal
|
|
Jan 9
|
GSK strikes £1.1bn deal for asthma drugmaker
|
|
Jan 9
|
GSK Enters Agreement to Acquire Aiolos Bio
|
|
Jan 9
|
Trending tickers: Apple | Samsung | GSK | Jupiter
|
|
Jan 9
|
GSK Expands Respiratory Pipeline With Aiolos Bio Buy
|